GENMAB A/S/S (OTCMKTS:GMXAY) Stock Passes Above 50 Day Moving Average – Here’s What Happened

Shares of GENMAB A/S/S (OTCMKTS:GMXAY) crossed above its 50 day moving average during trading on Thursday . The stock has a 50 day moving average of $28.32 and traded as high as $31.98. GENMAB A/S/S shares last traded at $31.94, with a volume of 3,427,175 shares.

GENMAB A/S/S Stock Performance

The firm has a 50 day moving average price of $28.32 and a 200-day moving average price of $27.92.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in GENMAB A/S/S stock. Madison Asset Management LLC bought a new stake in GENMAB A/S/S (OTCMKTS:GMXAY) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 70,781 shares of the company’s stock, valued at approximately $1,944,000.

GENMAB A/S/S Company Profile

Genmab A/S is a Denmark-based biotechnology company specializing in the creation and development of proprietary antibody therapeutics for the treatment of cancer and autoimmune diseases. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has focused on leveraging its innovative antibody platforms—such as DuoBody, HexaBody and DuoHexaBody—to generate next-generation therapies. The company’s expertise extends from early discovery through preclinical development, after which it partners with larger biopharmaceutical firms to advance candidates through clinical trials and commercialization.

Among Genmab’s most notable products is daratumumab, marketed under the brand name DARZALEX in collaboration with Janssen, which has become a leading monoclonal antibody for the treatment of multiple myeloma.